Van beleggers
voor beleggers
desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?

Ontvang nu dagelijks onze kooptips!

word abonnee

Wat na ABLYNX welke aandeln kunnen veel groeien om welke redenen.

3 Posts
| Omlaag ↓
  1. [verwijderd] 1 februari 2018 11:34
    Merus, bispecifieke antibodies zijn de toekomst. bivoorbeeld: Basel, June 28, 2016 - Today Novartis announced that it has entered into a collaboration and licensing agreement with Xencor for the development of bispecific antibodies for treating cancer. The agreement is the latest in a series of acquisitions and strategic collaborations between Novartis and biotech companies that have helped bolster its deep and diverse immuno-oncology pipeline.

    Traditional monoclonal antibodies target and bind to a single antigen. Bispecific antibodies are engineered to recognize and target two different antigens, which makes them potentially more effective in targeting complex diseases. A T-cell engaging bispecific antibody is able to bind an antigen on a tumor cell with one arm and engage T-cells capable of their destruction with the other.
3 Posts
|Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 881,57 +0,78%
EUR/USD 1,0682 -0,19%
FTSE 100 8.088,27 +0,54%
Germany40^ 18.198,60 +0,34%
Gold spot 2.318,39 -0,16%
NY-Nasdaq Composite 15.696,64 +1,59%

Stijgers

VIVORY...
+12,08%
ASMI
+10,99%
NX FIL...
+3,85%
RANDST...
+3,82%
BESI
+3,56%

Dalers

ALLFUN...
-7,90%
ING
-4,62%
Flow T...
-2,34%
DSM FI...
-0,99%
UMG
-0,73%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links